Danaher (DHR) Peer Comparison
$217.46
$-1.03
(-0.47%)
As on 08-Oct-2026 16:02EDT
Market cap
$148,864 Mln
Revenue (TTM)
$25,107 Mln
P/E Ratio
39.5
P/B Ratio
3
Div. Yield
0.7 %
Edit
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
148,864 | 241,264 | 168,712 | 140,427 | 104,700 |
Revenue ($ Mln) |
25,107 | 46,336 | 46,585 | 11,034 | 25,837 |
Net Profit ($ Mln) |
4,004.00 | 6,978.00 | 5,425.00 | 3,138.80 | 3,729.00 |
Net Margin (%) |
15.95 | 15.06 | 11.65 | 28.45 | 14.43 |
RoE (%) |
7.62 | 13.12 | 10.51 | 17.34 | 16.07 |
Price to Earnings |
39.51 | 35.40 | 31.55 | 46.06 | 28.58 |
Price-To-Book |
2.96 | 4.67 | 3.50 | 7.82 | 4.40 |
Income Statement ($ Mln)
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
25,107.00 | 46,336.00 | 46,585.00 | 11,034.40 | 25,837.00 |
|
Cost of Revenue
|
10,416.00 | 27,323.00 | 20,123.00 | 3,676.80 | 9,000.00 |
|
Gross Profit
|
14,970.00 | 18,239.00 | 24,607.00 | 6,642.30 | 16,065.00 |
|
Operating Expenses
|
9,564.00 | 10,685.00 | 18,557.00 | 3,906.40 | 11,146.00 |
|
Operating Profit (EBIT)
|
5,127.00 | 8,327.00 | 7,932.00 | 3,451.20 | 5,691.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
4,762.00 | 7,609.00 | 7,511.00 | 3,805.80 | 5,148.00 |
|
Provision for Tax
|
758.00 | 597.00 | 2,086.00 | 647.90 | 1,419.00 |
|
Profit after Tax (Net Income)
|
4,004.00 | 6,978.00 | 5,425.00 | 3,138.80 | 3,729.00 |
|
Minority Interest
|
0.00 | -21.00 | 0.00 | -19.10 | 0.00 |
|
Consolidated Profit
|
2,105.00 | 3,580.00 | 3,420.00 | 0.00 | 1,708.00 |
Liabilities ($ Mln)
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
52,581.00 | 52,679.00 | 51,110.00 | 18,168.40 | 23,988.00 |
|
Minority Interest
|
0.00 | -21.00 | 0.00 | -19.10 | 0.00 |
|
Non-Current Liabilities
|
31,681.00 | 45,298.00 | 39,639.00 | 656.00 | 17,258.00 |
|
Current Liabilities
|
8,105.00 | 15,069.00 | 17,814.00 | 1,922.90 | 6,684.00 |
|
Total Liabilities
|
83,464.00 | 110,343.00 | 86,713.00 | 20,631.20 | 47,844.00 |
Assets ($ Mln)
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
78,986.00 | 89,809.00 | 84,698.00 | 11,333.90 | 33,512.00 |
|
Current Assets
|
13,381.00 | 23,365.00 | 24,517.00 | 9,542.70 | 14,418.00 |
|
Total Assets
|
83,464.00 | 110,343.00 | 86,713.00 | 20,631.20 | 47,844.00 |
|
Total Debt*
|
26,558.00 | 42,549.00 | 32,608.00 | 0.00 | 14,942.00 |
|
Net Current Assets
|
5,276.00 | 8,296.00 | 0.00 | 7,619.80 | 7,734.00 |
Cashflow ($ Mln)
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
6,416.00 | 7,818.00 | 9,566.00 | 3,030.50 | 5,044.00 |
|
Cash Flow from Investing Activities
|
-1,196.00 | -4,047.00 | -2,422.00 | 665.80 | -4,866.00 |
|
Cash from Financing Activities
|
-2,961.00 | 1,801.00 | -6,309.00 | -2,364.10 | 113.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
5.25 | 7.69 | 10.03 | 16.46 | 8.83 |
|
ROE (%)
|
7.62 | 13.12 | 10.51 | 17.34 | 16.07 |
|
ROA (%)
|
4.24 | 5.76 | 4.69 | 14.06 | 6.89 |
|
EBIT Margin (%)
|
20.13 | 18.62 | 13.35 | 33.76 | 21.08 |
|
Net Margin (%)
|
15.95 | 15.06 | 11.65 | 28.45 | 14.43 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
4.56 | 7.23 | 8.06 | 20.66 | 8.48 |
|
EBIT Growth (%)
|
15.73 | 1.20 | -26.60 | 24.96 | 55.16 |
|
Net Profit Growth (%)
|
17.32 | 5.98 | -61.19 | 20.37 | 27.79 |
|
EPS Growth (%)
|
20.09 | 7.77 | -61.19 | 21.65 | 27.71 |
|
Book Value Growth (%)
|
2.10 | 6.26 | 1.54 | 3.40 | 13.32 |
Valuation Ratios
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
45.04 | 32.43 | 33.55 | 71.47 | 41.85 |
|
Price / Book Value
|
3.10 | 4.09 | 4.20 | 11.45 | 6.06 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
25.42 | 21.61 | 19.48 | 49.76 | 23.46 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.48 | 0.74 | 0.00 | 0.00 | 0.59 |
|
Short term debt to equity ratio
|
0.03 | 0.06 | 0.06 | 0.00 | 0.03 |
|
Current Ratio
|
1.65 | 1.55 | 1.38 | 4.96 | 2.16 |
|
Quick Ratio
|
1.25 | 1.18 | 0.97 | 3.91 | 1.33 |
|
Interest Coverage
|
17.31 | 6.19 | 12.79 | -- | 7.22 |
Operating Efficiency Ratios
| Danaher (DHR) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
15.79 | 20.40 | 18.46 | 16.08 | 14.49 |
|
Asset Turnover
|
0.27 | 0.38 | 0.40 | 0.49 | 0.48 |
|
Receivable days
|
61.72 | 82.76 | 61.20 | 54.16 | 58.36 |
|
Inventory Days
|
91.69 | 72.19 | 117.44 | 177.54 | 203.47 |
|
Payable days
|
68.44 | 46.50 | 78.11 | 23.93 | 70.18 |
|
Cash Conversion Cycle
|
84.97 | 108.45 | 100.53 | 207.78 | 191.65 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
